Core Insights - The virtual panel discussion will focus on the plaque psoriasis landscape, treatment options, unmet needs, and the potential of Scinai's anti-IL-17A/F VHH antibodies [2][3] - Scinai Immunotherapeutics is a biopharmaceutical company with a focus on developing innovative nanosized VHH antibodies for inflammation and immunology [4] Group 1: Panel Discussion Details - The panel will include key figures such as Mr. Amir Reichman (CEO of Scinai), Dr. Tamar Ben Yedidia (Chief Scientific Officer), and professors from UMG and Max Planck Institute [1] - The discussion will cover the current treatment landscape for plaque psoriasis, the science behind single domain VHH antibodies, and Scinai's drug development process [2] Group 2: Scinai's Business Model - Scinai operates two business units: one for in-house development of biological therapeutic products and another as a boutique CDMO for early-stage biotech projects [4] - The company is developing a novel anti-IL-17 VHH antibody for psoriasis treatment, with plans for clinical trials and a target product profile for intralesional application [2][4] Group 3: Engagement Opportunities - Participants in the webinar will have the chance to submit questions and engage in a Q&A session at the end of the discussion [3]
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies